UNASSIGNED: 4586 Background: Clinical response in second-line treatment of @entity5 after @entity900 -failure may differ substantially. @entity74 during treatment with survival of only a few weeks as well as long-term survival of several years is possible. Aim of this analysis was to validate the prognostic model for survival developed by Bellmunt et al. in a different @entity1 -cohort. METHODS: Baseline parameters (BPs) of 102 @entity1 (pts.) derived from the largest phase III trial of second-line chemotherapy with @entity136 and @entity1311 (GP) were compared to the phase III cohort of @entity24986 versus best supportive care (n = 370). Uni- and multivariate analyses of BPs with respect to @entity1349 ( @entity1349 ) were performed. Pts. were stratified according to the Bellmunt model (ECOG > 1, hemoglobin < 10 g/dl, @entity99 ) and altered models. @entity1349 of subgroups was compared by log-rank test. Accuracy of the different models to identify subgroups with favorable and poor survival was tested by ROC-analysis. RESULTS: BPs were comparable. The identification of prognostic subgroups by Bellmunt with significant difference in @entity1349 could be validated (11.8 [95%CI 6.3-17.3], 8.1 [95%CI 4.8-11.4], 3.2 [95%CI 0.0-7.9] months, P=.007). The prediction of poor (AUC=0.660, P=.023) as well as favorable (AUC=0.634, P=.036) prognosis was possible. A different hemoglobin cut-off value (<12 g/dl) was identified as a poor prognostic factor in a multivariate analysis (HR 1.485, P<.001) and resulted in a better discrimination of pts. @entity1349 (14.1 [95% CI 7.5-20.7], 10.9 [95% CI 4.9-16.9], 5.7 [95% CI 4.6-6.8], 3.2 [95% CI 1.5-3.1] months, P<.001). However, apart from the Bellmunt parameters lymph-node-only disease was the strongest predictor of prolonged @entity1349 and overruled every other single Bellmunt parameter in a multivariate analysis (HR 0.506, P=.001). CONCLUSIONS: The Bellmunt risk factor model was validated in the GP cohort. Lymph-node-only disease was identified as a favorable factor for @entity1349 which overrules the prognostic model. Therefore, in these @entity1 every treatment option should be taken into account, even if @entity417 or @entity73 performance status is present.

Prognostic factors in second-line treatment of @entity5 with @entity136 and XXXX : German Association of Urological Oncology (AUO) trial AB 20/99.

@entity1 :: ('9606', 'Species') :: ['patients', 'patient'] @entity417 :: ('MESH:D000740', 'Disease') :: ['anemia'] @entity24986 :: ('MESH:C111217', 'Chemical') :: ['vinflunine'] @entity5 :: ('MESH:D009369', 'Disease') :: ['urothelial cancers'] @entity73 :: ('MESH:D003072', 'Disease') :: ['impaired'] @entity900 :: ('MESH:D002945', 'Chemical') :: ['cisplatin'] @entity1311 :: ('MESH:D017239', 'Chemical') :: ['paclitaxel'] @entity74 :: ('MESH:D030342', 'Disease') :: ['Progressive disease'] @entity99 :: ('MESH:D056486', 'Disease') :: ['hepatic disease'] @entity136 :: ('MESH:C056507', 'Chemical') :: ['gemcitabine'] @entity1349 :: ('MESH:D011475', 'Disease') :: ['OS', 'overall survival']
@entity1311 :: (MESH:D017239,Chemical) :: ['paclitaxel']
